Etid klinik pou Psoryaz nan Texas
8 etid pou Psoryaz ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
- Precision Comprehensive Research, Colleyville
- Rheumatology Associates of South Texas, San Antonio
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Sep 25, 2026 · NCT07801495Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- ak 2 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
- Vanda Investigational Site, San Antonio
- Vanda Investigational Site, Webster
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 22, 2026 · NCT07362017A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Bellaire Dermatology Associates, Bellaire
- Modern Research Associates, PLLC, Dallas
- Center for Clinical Studies, Houston
- ak 3 plis
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06857942A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Texas Dermatology and Laser Specialists, San Antonio
- Local Institution - 0280, Southlake
Ap rekriteFaz 3
Laj 12 a 17 · Tout sèks · Mizajou Sep 3, 2026 · NCT06979453A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
- Study Center, San Antonio
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jul 9, 2026 · NCT07489885Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- M D Anderson Cancer Center, Houston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT04751396Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
- Clinical Investigations of Texas, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 19, 2025 · NCT06982352Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.